Elevation Point Wealth Partners LLC Acquires New Holdings in Natera, Inc. $NTRA

Elevation Point Wealth Partners LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) during the 1st quarter, Holdings Channel reports. The institutional investor bought 6,529 shares of the medical research company’s stock, valued at approximately $1,306,000.

Several other large investors also recently modified their holdings of NTRA. JPMorgan Chase & Co. increased its position in Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP boosted its position in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp grew its stake in shares of Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the period. Franklin Resources Inc. grew its stake in shares of Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the period. Finally, Coatue Management LLC increased its position in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $283.80 on Tuesday. The company has a market capitalization of $40.64 billion, a P/E ratio of -174.11 and a beta of 1.51. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04. The firm’s 50 day simple moving average is $221.45 and its two-hundred day simple moving average is $217.64.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,405 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the sale, the insider owned 142,295 shares in the company, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 in the last three months. Corporate insiders own 5.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Evercore restated an “outperform” rating and set a $300.00 target price on shares of Natera in a research report on Monday. Sanford C. Bernstein initiated coverage on shares of Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 target price for the company. Royal Bank Of Canada began coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target on the stock. Finally, Wolfe Research began coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $262.00.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.